Related Experiment Video
Updated: May 19, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia
1Faculty of Life Sciences, The University of Manchester, Manchester, UK.
Abstract:
Glucocorticoids (GCs) are among the most widely prescribed medications in clinical practice. The beneficial effects of GCs in acute lymphoblastic leukemia (ALL) are based on their ability to induce apoptosis, but the underlying transcriptional mechanisms remain poorly defined. Computational modeling has enormous potential in the understanding of biological processes such as apoptosis and the discovery of novel regulatory mechanisms. We here present an integrated analysis of gene expression kinetic profiles using microarrays from GC sensitive and resistant ALL cell lines and patients, including newly generated and previously published data sets available from the Gene Expression Omnibus. By applying time-series clustering analysis in the sensitive ALL CEM-C7-14 cells, we identified 358 differentially regulated genes that we classified into 15 kinetic profiles. We identified GC response element (GRE) sequences in 33 of the upregulated known or potential GC receptor (GR) targets. Comparative study of sensitive and resistant ALL showed distinct gene expression patterns and indicated unexpected similarities between sensitivity-restored and resistant ALL. We found that activator protein 1 (AP-1), Ets related gene (Erg) and GR pathways were differentially regulated in sensitive and resistant ALL. Erg protein levels were substantially higher in CEM-C1-15-resistant cells, c-Jun was significantly induced in sensitive cells, whereas c-Fos was expressed at low levels in both. c-Jun was recruited on the AP-1 site on the Bim promoter, whereas a transient Erg occupancy on the GR promoter was detected. Inhibition of Erg and activation of GR lead to increased apoptosis in both sensitive and resistant ALL. These novel findings significantly advance our understanding of GC sensitivity and can be used to improve therapy of leukemia.
Insights
Glucocorticoids (GCs) induce apoptosis in acute lymphoblastic leukemia (ALL). This study reveals distinct gene expression patterns in GC-sensitive and resistant ALL, identifying key pathways for improved leukemia therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Glucocorticoids (GCs) are widely used for acute lymphoblastic leukemia (ALL) treatment, primarily by inducing apoptosis.
- The precise transcriptional mechanisms underlying GC efficacy and resistance in ALL remain incompletely understood.
Purpose of the Study:
- To investigate the gene expression kinetic profiles in GC-sensitive and resistant ALL using integrated computational analysis.
- To identify novel regulatory mechanisms and pathways involved in GC sensitivity and resistance in ALL.
Main Methods:
- Integrated analysis of gene expression kinetic profiles from microarray data of ALL cell lines and patients.
- Time-series clustering analysis to identify differentially regulated genes and kinetic profiles.
- Identification of Glucocorticoid Response Element (GRE) sequences and analysis of transcription factor binding (AP-1, Erg, GR).
Main Results:
- 358 differentially regulated genes were identified in sensitive ALL cells, classified into 15 kinetic profiles.
- Distinct gene expression patterns were observed between sensitive and resistant ALL, with unexpected similarities in sensitivity-restored and resistant ALL.
- The activator protein 1 (AP-1), Ets related gene (Erg), and Glucocorticoid Receptor (GR) pathways were differentially regulated. Erg levels were higher in resistant cells, while c-Jun was induced in sensitive cells.
- c-Jun binding to the Bim promoter and transient Erg occupancy on the GR promoter were detected.
Conclusions:
- Inhibition of Erg and activation of GR enhance apoptosis in both GC-sensitive and resistant ALL.
- These findings provide novel insights into GC sensitivity mechanisms and offer potential targets for improving leukemia therapy.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
TGF - β Signaling Pathway
Mitogens and the Cell Cycle
Lineage Commitment
